Since its discovery in 1984, Tacrolimus has proven itself to be an invaluable tool in the armamentarium of immunosuppression after organ transplantations. Tacrolimus was first introduced as a rescue therapy in liver transplant patients and quickly showed promise in its ability to improve patient and graft survival, while nowadays there is data demonstrating its effectiveness as a monotherapy immunosuppressive regimen after liver transplantation. Moreover, Tacrolimus shows promising results in the fields of regenerative response after transplantation, dermatology, multiple autoimmune diseases, healing of colonic anastomoses, platelet activity and thrombotic disorders and Hereditary Hemorrhagic Telangiectasia (HHT). This hardcover edition comprehensively discusses different issues and aspects concerning the multimodal effects and the safety of this widely used, relatively new, immunosupressant and could be considered an optimal tool for every clinician, since the action of Tacrolimus is no longer limited to post-transplant patients but also extends to its usage in multiple medical fields.